-- Akebia Therapeutics (AKBA) 週一宣布，其用於治療心臟手術相關急性腎損傷的藥物 AKB-9090 的 I 期臨床試驗已完成首批受試者的給藥。 Akebia Therapeutics 表示，該研究將評估 AKB-9090 在健康成年受試者中靜脈注射給藥的安全性、耐受性、藥物動力學和藥效學，併計劃招募至多 70 名受試者。 Akebia Therapeutics 執行長 John Butler 在一份聲明中表示，該公司計劃於 2027 年初公佈該研究的主要數據。
Related Articles
Asia
Hongqiao Aluminum's Profit Jumps 38%, Revenue Up 3%
Shandong Hongqiao Aluminum Industry (SHE:002379) reported a 38% jump in attributable net profit in the first quarter of 2026 to 6.76 billion yuan from 4.91 billion yuan, according to a filing on the Shenzhen Stock Exchange over the weekend.Diluted earnings per share rose to 0.5186 yuan from 0.3770 yuan.The aluminum company's revenue edged up 3.21% to 40.9 billion yuan from 39.7 billion yuan.
$SHE:002379
Asia
Cofoe Medical Technology Seeks Up to HK$1.06 Billion in Hong Kong IPO
Cofoe Medical Technology (HKG:1187, SHE:301087) launched its Hong Kong initial public offering on Monday, seeking to raise up to about HK$1.06 billion from the deal.The China-based home care medical device provider is offering 27 million H-shares at a maximum offer price of HK$39.33 per share, according to a Hong Kong bourse filing.The offering comprises 2.7 million shares for Hong Kong investors and 24.3 million shares for international investors, subject to reallocation.The offer price is expected to be determined by May 4, with allocation results due by May 5, ahead of the company's planned trading debut on May 6.Net proceeds will be used mainly to support global expansion and strengthen overseas sales channels, as well as advance product research and development.The funds will also be used to expand domestic distribution networks, enhance branding and marketing efforts, and for working capital and general corporate purposes.Huatai Financial Holdings (Hong Kong) and BNP Paribas Securities (Asia) are acting as joint sponsors.Huatai Financial Holdings (Hong Kong) and BNP Paribas Securities (Asia) are serving as overall coordinators and are also acting as joint bookrunners and joint lead managers, alongside Futu Securities International (Hong Kong).
$HKG:1187$SHE:301087
Asia
CMOC Group's Q1 Profit Nearly Doubles as Revenue Jumps 44%
CMOC Group (SHA:603993, HKG:3993) reported a 97% jump in attributable net profit in the first quarter of 2026 to 7.76 billion yuan from 3.95 billion yuan a year ago, according to filings on the Shanghai and Hong Kong bourses over the weekend.Diluted earnings per share doubled to 0.36 yuan from 0.18 yuan.The copper and cobalt producer's revenue edged up 44% to 66.4 billion yuan from 46 billion yuan.
$HKG:3993$SHA:603993